Should You Buy IRadimed Corp (IRMD) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/29
IRMD is not a good buy right now for an impatient investor. The stock is trading near/just below key resistance (pivot ~100.88) with weakening momentum (bearish MACD), and analyst targets ($98–$100) imply limited near-term upside from ~$99.35. Fundamentals are strong, but the technical setup suggests better entries are likely on a pullback rather than chasing here.
Technical Analysis
Trend/Momentum: MACD histogram is -0.599 and negatively expanding, which signals bearish momentum building despite the recent +1.29% close. RSI(6) ~41.7 is neutral-to-soft (not oversold), so there’s room for downside before a typical mean-reversion buy signal.
Moving Averages: Converging MAs suggest the trend is undecided and could break either way; combined with negative MACD, the balance tilts slightly bearish near-term.
Levels: Price ~$99.35 is below the pivot at 100.882 (near-term resistance). Support sits at S1 97.646 then S2 95.648; resistance is R1 104.118.
Pattern-based odds: Similar candlestick-pattern analysis suggests a 70% chance of ~-3.93% next day (near-term weakness), but +3.58% next week and +11.35% next month (medium-term constructive).
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Analyst Ratings and Price Target Trends
Recent Street trend is clearly positive: multiple reiterations of Buy and price-target raises. Roth Capital raised PT to $98 (from $90) and maintained Buy after the Q3 beat and guidance raise; Lake Street raised PT to $100 (from $75) and kept Buy, citing backlog visibility and the new pump launch as a 2026 growth driver.
Wall Street pros: Strong backlog/visibility, high margins, next-gen product cycle potential, guidance momentum.
Wall Street cons: Premium valuation acknowledged by analysts; with shares near $99, upside to updated targets looks limited in the immediate term.
Influential/political trading: No recent congress trading data available; hedge funds/insiders show neutral activity per provided trends.
Wall Street analysts forecast IRMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99 USD with a low forecast of 98 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast IRMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99 USD with a low forecast of 98 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 99.180
Current: 99.180
